BRIEF-Astrazeneca says U.S. FDA approved BEVESPI aerosphere inhalation aerosol indicated for treatment of patients with chronic obstructive pulmonary disease

* US FDA approved BEVESPI aerosphere inhalation aerosol

indicated for treatment of patients with chronic obstructive

pulmonary disease

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1 646 223 8780)

Read more